Department of Neurology, Ludwig-Maximilians-University, Munich, Germany.
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Mov Disord. 2021 Sep;36(9):2104-2115. doi: 10.1002/mds.28624. Epub 2021 May 5.
Corticobasal syndrome is associated with cerebral protein aggregates composed of 4-repeat (50% of cases) or mixed 3-repeat/4-repeat tau isoforms (25% of cases) or nontauopathies (~25% of cases).
The aim of this single-center study was to investigate the diagnostic value of the tau PET-ligand [ F]PI-2620 in patients with corticobasal syndrome.
Forty-five patients (71.5 ± 7.6 years) with corticobasal syndrome and 14 age-matched healthy controls underwent [ F]PI-2620-PET. Beta-amyloid status was determined by cerebral β-amyloid PET and/or CSF analysis. Subcortical and cortical [ F]PI-2620 binding was quantitatively and visually compared between β-amyloid-positive and -negative patients and controls. Regional [ F]PI-2620 binding was correlated with clinical and demographic data.
Twenty-four percent (11 of 45) were β-amyloid-positive. Significantly elevated [ F]PI-2620 distribution volume ratios were observed in both β-amyloid-positive and β-amyloid-negative patients versus controls in the dorsolateral prefrontal cortex and basal ganglia. Cortical [ F]PI-2620 PET positivity was distinctly higher in β-amyloid-positive compared with β-amyloid-negative patients with pronounced involvement of the dorsolateral prefrontal cortex. Semiquantitative analysis of [ F]PI-2620 PET revealed a sensitivity of 91% for β-amyloid-positive and of 65% for β-amyloid-negative cases, which is in excellent agreement with prior clinicopathological data. Regardless of β-amyloid status, hemispheric lateralization of [ F]PI-2620 signal reflected contralateral predominance of clinical disease severity.
Our data indicate a value of [ F]PI-2620 for evaluating corticobasal syndrome, providing quantitatively and regionally distinct signals in β-amyloid-positive as well as β-amyloid-negative corticobasal syndrome. In corticobasal syndrome, [ F]PI-2620 may potentially serve for a differential diagnosis and for monitoring disease progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
皮质基底节综合征与由 4 重复（50%的病例）或混合 3 重复/4 重复 tau 异构体（25%的病例）或非 tau 病变组成的脑蛋白聚集体有关（~25%的病例）。
本单中心研究旨在探讨 tau PET 配体[F]PI-2620 在皮质基底节综合征患者中的诊断价值。
45 例皮质基底节综合征患者（71.5±7.6 岁）和 14 名年龄匹配的健康对照者接受[F]PI-2620-PET 检查。通过脑β-淀粉样蛋白 PET 和/或 CSF 分析确定β-淀粉样蛋白状态。定量和视觉比较β-淀粉样蛋白阳性和阴性患者与对照组之间的皮质基底节[F]PI-2620 结合。区域[F]PI-2620 结合与临床和人口统计学数据相关。
24%（45 例中有 11 例）为β-淀粉样蛋白阳性。与对照组相比，β-淀粉样蛋白阳性和阴性患者的背外侧前额叶皮层和基底节均可见明显升高的[F]PI-2620 分布容积比。与β-淀粉样蛋白阴性患者相比，β-淀粉样蛋白阳性患者的皮质[F]PI-2620 PET 阳性率明显更高，且背外侧前额叶皮层明显受累。[F]PI-2620 PET 的半定量分析显示，β-淀粉样蛋白阳性病例的敏感性为 91%，β-淀粉样蛋白阴性病例的敏感性为 65%，与先前的临床病理数据非常吻合。无论β-淀粉样蛋白状态如何，[F]PI-2620 信号的半球侧化均反映了临床疾病严重程度的对侧优势。
我们的数据表明[F]PI-2620 对评估皮质基底节综合征具有价值，在β-淀粉样蛋白阳性和阴性的皮质基底节综合征中提供定量和区域独特的信号。在皮质基底节综合征中，[F]PI-2620 可能有助于鉴别诊断和监测疾病进展。
